Lila Sciences is nearing a massive Series A funding round exceeding $300 million, as reported exclusively by Endpoints News. The company aims to back its vision of building "scientific superintelligence" through this oversubscribed megaround. Such substantial capital injection will accelerate Lila's development of autonomous scientific discovery tools, likely impacting biotech innovation and automation significantly. The raise also signals strong investor confidence in AI-driven biotech startups.